Clinical Trial News

Dr. Curis joined the ECHO research team in October 2024. He attended the University of Rhode Island for his undergraduate bachelor’s degree in Biological and Health Sciences. He then attended Avalon University School of Medicine for his medical doctorate. He […]

Research is a core focus at Eastern Connecticut Hematology & Oncology (ECHO). For over 35 years, we have excelled at bringing the latest advancements and treatments to patients across Eastern Connecticut. This includes offering our patients the possibility to participate in promising […]

Beigene’s CELESTIAL Trial This clinical trial is for patients who have experienced progression of chronic lymphocytic leukemia.  The usual first line treatment includes a BTK inhibitor (ibrutinib, acalabrutinib, zanubrutinib , pirtoburtinib) or the combination of venetoclax with obinutuzumab.  Some patients […]

The Beigene’s CELESTIAL clinical trial for chronic lymphocytic leukemia This clinical trial is for patients who have experienced progression of chronic lymphocytic leukemia.  The usual first line treatment includes a BTK inhibitor (ibrutinib, acalabrutinib, zanubrutinib , pirtoburtinib) or the combination […]

Below is information on the INTerpath 009 study which is a clinical trial for early-stage non-small cell lung cancer (NSCLC). This clinical trial is trying to determine if an investigational study drug combination, when given after initial treatment and surgery, […]

A Phase 3 randomized double-blind study of adjuvant pembrolizumab with or without V940 in participants with resectable Stage II to IIIB (N 2) non-small cell lung cancer who are not achieving pCR after receiving neoadjuvant pembolizumab with platinum-based doublet chemotherapy […]